This week's Lab Notes has items on a cell therapy developer joining the list of life sciences companies making staff reductions, a multimillion-dollar debt financing deal, an update on a company's efforts to develop biosimilar products and more.
Here's the Roundup
AdaptImmune (NASDAQ: ADAP)
The cell therapy developer with operations in Philadelphia and Oxford, England, said this week it is cutting its workforce by 25% to 30% and narrowing its research focus to conserve cash.
An Adaptimmune spokeswoman…
